M Vourvahis

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    HIV Clin Trials 14:99-109. 2013
  2. doi request reprint Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, NY 10017, USA
    Drug Alcohol Depend 126:183-8. 2012
  3. pmc Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    Antimicrob Agents Chemother 56:4303-9. 2012
  4. doi request reprint The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects
    Manoli Vourvahis
    Department of Clinical Pharmacology, Pfizer Global Research and Development, New York, NY, USA
    J Acquir Immune Defic Syndr 60:24-32. 2012
  5. pmc No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    Antimicrob Agents Chemother 56:2408-13. 2012
  6. doi request reprint Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy vo
    Manoli Vourvahis
    Pfizer Global R and D, 50 Pequot Avenue, New London, CT 06320, USA
    Drug Metab Dispos 38:789-800. 2010
  7. pmc Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine
    M Vourvahis
    Pfizer Global Research and Development, New London, CT 06320, USA
    Antimicrob Agents Chemother 54:2209-11. 2010
  8. pmc Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    Antimicrob Agents Chemother 56:887-92. 2012

Detail Information

Publications8

  1. doi request reprint Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    HIV Clin Trials 14:99-109. 2013
    ..Reference to local prescribing information is recommended, because dose recommendations in renally impaired patients may differ between regions. ..
  2. doi request reprint Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, NY 10017, USA
    Drug Alcohol Depend 126:183-8. 2012
    ..This study evaluated the effect of lersivirine on the pharmacokinetics (PK) of R- and S-methadone enantiomers...
  3. pmc Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    Antimicrob Agents Chemother 56:4303-9. 2012
    ..No dose adjustment of rifabutin is necessary in the presence of lersivirine; an upward dose adjustment of lersivirine may be warranted when it is coadministered with rifabutin...
  4. doi request reprint The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects
    Manoli Vourvahis
    Department of Clinical Pharmacology, Pfizer Global Research and Development, New York, NY, USA
    J Acquir Immune Defic Syndr 60:24-32. 2012
    ..Four studies evaluated the pharmacokinetic (PK) interactions between lersivirine and various HIV-1 protease inhibitors...
  5. pmc No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    Antimicrob Agents Chemother 56:2408-13. 2012
    ..LRV (2,400 mg) did not prolong the QTcF interval, and no clinically relevant electrocardiogram or vital sign changes were observed in healthy subjects...
  6. doi request reprint Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy vo
    Manoli Vourvahis
    Pfizer Global R and D, 50 Pequot Avenue, New London, CT 06320, USA
    Drug Metab Dispos 38:789-800. 2010
    ..In vitro studies showed that UGT2B7 and CYP3A4 are responsible for the majority of lersivirine metabolism in humans...
  7. pmc Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine
    M Vourvahis
    Pfizer Global Research and Development, New London, CT 06320, USA
    Antimicrob Agents Chemother 54:2209-11. 2010
    ..86%, showing that coadministration of an antacid had no effect on lersivirine exposure. Coadministration appeared to be safe and relatively well tolerated...
  8. pmc Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects
    Manoli Vourvahis
    Pfizer Global Research and Development, New York, New York, USA
    Antimicrob Agents Chemother 56:887-92. 2012
    ..4 to +8.6%). Lersivirine appeared to be generally well tolerated in these studies and appears to be suitable for coadministration with raltegravir or maraviroc without the need for dose modification...